Tampa General Hospital Sues Eli Lilly Over 340B Program Discount Removal
Tampa General Hospital has initiated a lawsuit against Eli Lilly and Company, challenging the pharmaceutical giant’s recent policy changes regarding the 340B drug pricing program. The hospital describes Lilly’s actions as “unconscionable and immoral,” following the drugmaker’s decision to withdraw discounts for non-compliant providers.
Background on the 340B Program and Recent Policy Changes
The 340B program is a federal initiative designed to enable safety-net hospitals to purchase outpatient drugs at reduced prices, thereby extending more affordable healthcare to vulnerable populations. Earlier this year, Eli Lilly implemented a policy mandating providers to submit claims-level data for all pharmacy and medical dispensaries. The company warned that non-compliance would result in the removal of discounts, a threat that materialized for some hospitals last month, including Tampa General.
Impact on Tampa General Hospital
Tampa General, a large hospital with nearly 1,000 beds, reported a significant increase in costs—between 25% to 50% more on Lilly products—due to the withdrawal of these discounts. The hospital argues that many of these products are essential and available only through Lilly, emphasizing the drugmaker’s monopoly power.
Legal Allegations and Hospital’s Stance
The lawsuit, filed in the U.S. District Court in the Middle District of Florida, accuses Lilly of violating the Florida Deceptive and Unfair Trade Practices Act. The hospital claims that the drugmaker’s actions undermine the 340B program’s mission to support healthcare for at-risk patients and are inconsistent with Lilly’s status as the world’s largest pharmaceutical company by market capitalization.
“The most valuable pharmaceutical company in the world is conducting a campaign to divert dollars earmarked for charitable purposes into its own pocket,” the lawsuit states. “The direct and inevitable result of Lilly’s actions is diminished health care for poor people. Her actions shock the conscience and are patently irresponsible.”
Lilly’s Response and Broader Industry Context
A spokesperson for Lilly criticized the lawsuit, suggesting it is part of a broader effort by hospitals to resist transparency and conceal alleged fraud within the 340B program. Lilly contends that the claims data it requires is already collected by hospitals for insurers and that sharing this data is essential to prevent duplicate discounts under overlapping programs.
“The claims data that Lilly requires from hospitals is information that they already collect and regularly send to insurers,” the Lilly spokesperson stated. “Refusing to share the same data with Lilly shows that hospitals are more concerned with hiding rampant abuse in the program than improving its integrity. Lilly will continue to work to ensure that this program serves vulnerable patients, not hospitals and their for-profit partners.”
Ongoing Controversies and Legislative Developments
The 340B program has become a focal point for industry and policy debates, particularly as its scope has expanded. The recent legal actions are reminiscent of conflicts from earlier this year, such as the Trump administration’s attempt to launch a pilot discount program, which faced legal challenges from the hospital industry.
Additionally, the Centers for Medicare and Medicaid Services recently proposed a significant cut in 340B reimbursements, reducing them to 33.4% below the average selling price, further complicating the landscape for 340B providers.
For further details, please refer to the original source Here.
“`
